GynecologyGynecology2079-56962079-5831Consilium Medicum28206Research ArticleVulvovaginitis and vaginosis treatment: clinical and laboratory efficiencyPrilepskayaV N-MezhevitinovaE Amejevitinova@mail.ruAbakarovaP Rabakarova2002@mail.ruBrovkinaT V-PogosyanSh M-150820131544909042020Copyright © 2013, Consilium Medicum2013A study to assess the clinical and laboratory efficacy of Terzhinan in patients with different vulvovaginal etiologies was held. The study included 230 women of reproductive age diagnosed with vulvovaginitis, selected by random sampling. For the diagnosis specification all women were put through a thorough general medical examination by a single algorithm no later than 2–4 days before the start of treatment (runtime microbiology). All patients were divided into 4 general groups and the control group. The first group consisted of 45 (19,6%) women with a diagnosis of «nonspecific vaginitis» (NV), the second – of 43 (18,8%) women with a «bacterial vaginosis» diagnosis (BV), a third – of 41 (17,8%) women with a diagnosis of «vulvovaginal candidiasis» (VVC), and in 47 (20,3%) of the women in group 4 mixed infection was found and 54 (23,5%) of women were united into the control group. Terzhinan was prescribed as therapy to all groups, following the scheme of 1 tablet vaginally 1 time a day at bedtime for 10 days. A total of 176 women from four first groups were treated. After the treatment some complaints about genital discharge remained the same in only 28 (15,9%) women, of itching and burning – in 1 (0,6%) woman, 6 (3,4%) women complained of dyspareunia, and 2 (1,1%) women complained of vulvar discomfort. Three months after the end of therapy of all 176 women surveyed, 1 woman was diagnosed with NV, 1 other woman was diagnosed with BV, 1 – with VVC, and none contracted mixed infection. All 3 patients with recurrences were re-assigned to a course of treatment. 6 months after the end of treatment, 2 cases of recurrent VVC, 1 case – BT and 1 mixed infection were noted. Patients in all groups, where Terzhinan was used, noted a health improvement and a significant reduction in symptoms on the third day of treatment, which demonstrates the effectiveness of the local comprehensive anti-inflammatory therapy. Conclusions. Terzhinan is an effective treatment of nonspecific vaginitis, bacterial vaginosis and vulvovaginal candidiasis. Its application showed a high percentage of curability and the minimum number of relapses was noted. No complications or allergic reactions were registered after treatment.vulvovaginitisnonspecific vulvovaginitisbacterial vaginosisvulvovaginal candidiasistreatment of vulvovaginitisвульвовагинитнеспецифический вульвовагинитбактериальный вагинозкандидозный вульвовагиниттерапия вульвовагинитов[Бондаренко К.Р. Этиопатогенетические особенности бактериального вагиноза у женщин репродуктивного возраста. Автореф. дис.. канд. мед. наук. Уфа, 2009; с. 18.][Громова О.Л., Торшин И.Ю., Гарасько Е.А. Молекулярные механизмы топического назначения витамина С в лечении бактериального вагиноза. Акуш. и гинекол. 2010; 11: 37–42.][Доброхотова Ю.Э., Затикян Н.Г. Влияние контрацептивного средства Нова - Ринг на микробиоценоз влагалища у женщин репродуктивного возраста. Рос. вестн. акушера - гинеколога. 2007; 7 (3): 59–62.][Мавзютов А.Р., Бондаренко К.Р., Бондаренко В.М. Бактериальный вагиноз: этиопатогенетические аспекты. Журн. микробиол., эпидемиол. и иммунол. 2007; 6: 93–100.][Методические материалы по диагностике и лечению наиболее распространенных инфекций, передаваемых половым путем, и заболеваний кожи. Под ред. А.А.Курбановой. М.: ГЭОТАР - МЕД, 2003.][Наумкина Е.В., Рудаков Н.В., Пахалкова Е.В. Виды Ureaplasma urealiticum в этиологии урогенитальных микст - инфекций. Журн. микробиол., эпидемиол. и иммунол. 2006; 3: 93–5.][ПЦР и ее применение для диагностики в дерматовенерологии. Под ред. А.А.Воробьева. М.: Мед. информ. агентство, 2004.]